Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax, Inc. , a global company advancing protein-based vaccines with its Matrix-Mtm adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...
Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...
Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...